275 related articles for article (PubMed ID: 15785241)
1. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
Park JW; Zarnegar R; Kanauchi H; Wong MG; Hyun WC; Ginzinger DG; Lobo M; Cotter P; Duh QY; Clark OH
Thyroid; 2005 Mar; 15(3):222-31. PubMed ID: 15785241
[TBL] [Abstract][Full Text] [Related]
2. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Ohta K; Endo T; Haraguchi K; Hershman JM; Onaya T
J Clin Endocrinol Metab; 2001 May; 86(5):2170-7. PubMed ID: 11344222
[TBL] [Abstract][Full Text] [Related]
3. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Fröhlich E; Machicao F; Wahl R
Endocr Relat Cancer; 2005 Jun; 12(2):291-303. PubMed ID: 15947104
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines.
Park JW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
Thyroid; 2003 Dec; 13(12):1103-10. PubMed ID: 14751030
[TBL] [Abstract][Full Text] [Related]
6. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.
Benson S; Wu J; Padmanabhan S; Kurtz TW; Pershadsingh HA
Am J Hypertens; 2000 Jan; 13(1 Pt 1):74-82. PubMed ID: 10678274
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Fiatte C; Huin C; Bertin I; Lesuffleur T; Pluvinet A; Touche N; Plénat F; Dauça M; Domenjoud L; Schohn H
Int J Oncol; 2006 Dec; 29(6):1601-10. PubMed ID: 17089002
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.
He G; Thuillier P; Fischer SM
J Invest Dermatol; 2004 Dec; 123(6):1110-9. PubMed ID: 15610522
[TBL] [Abstract][Full Text] [Related]
12. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
14. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
[TBL] [Abstract][Full Text] [Related]
15. Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.
Ming M; Yu JP; Meng XZ; Zhou YH; Yu HG; Luo HS
World J Gastroenterol; 2006 Dec; 12(45):7263-70. PubMed ID: 17143939
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1.
Gao M; Hu Z; Zheng Y; Zeng Y; Shen X; Zhong D; He F
Shock; 2011 Sep; 36(3):228-34. PubMed ID: 21617575
[TBL] [Abstract][Full Text] [Related]
18. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
[TBL] [Abstract][Full Text] [Related]
19. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
[TBL] [Abstract][Full Text] [Related]
20. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
Ban JO; Kwak DH; Oh JH; Park EJ; Cho MC; Song HS; Song MJ; Han SB; Moon DC; Kang KW; Hong JT
Chem Biol Interact; 2010 Oct; 188(1):75-85. PubMed ID: 20540935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
